Bisphosphonate therapy in an infant with generalized arterial calcification with an ABCC6 mutation

• Published in: Osteoporosis international 2018-11, Vol.29 (11), p.2575-2579
• Main Authors: Akhtar Ali, S., Ng, C., Votava-Smith, J. K., Randolph, L. M., Pitukcheewanont, P.
• Format: Article
• Language: English
• Subjects: Aorta; Aortic arch; Arteriosclerosis; Bisphosphonates; Calcification; Calcification (ectopic); Calcinosis; Case Report; Coronary vessels; Echocardiography; Endocrinology; Etidronic acid; Fetuses; Genetic disorders; Medicine; Medicine & Public Health; Mutation; Orthopedics; Pamidronic acid; Patients; Point mutation; Pregnancy; Pulmonary arteries; Pulmonary artery; Rheumatology; Stenosis; Ultrasonic imaging
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-018-4639-x

Generalized arterial calcification of infancy (GACI) is a rare genetic disorder with high infantile mortality, described to be due to ENPP1 , and less commonly ABCC6 mutations. Bisphosphonate treatment has been described to improve survival in ENPP1-positive GACI patients, but few studies have described bisphosphonate treatment in ABCC6-positive patients. Without therapy, patients will die before 6 months of age. Our patient is now 3 years old, former recipient twin of twin-to-twin transfusion syndrome (TTTS). Initial fetal echocardiogram at 19 weeks showed calcifications of the ascending aorta and pulmonary artery (PA). She underwent utero laser therapy, and despite resolution of the TTTS, her follow-up scans showed progressive calcification of the aorta and PA. Postnatal echocardiogram showed calcification and supravalvar stenosis of the aorta and PA. CT on day of life 6 showed calcifications in the PAs, aortic arch, and descending aorta. Quantification of valvular calcification can be difficult; in our patient, increasing outflow tract gradient on echocardiogram was used to monitor disease progression. Molecular testing revealed an ABCC6 gene mutation. She was started on weekly IV pamidronate (0.1–0.3 mg/kg/week) on day 8 of life then transitioned to oral etidronate (15–20 mg/kg/day). Given progressive supravalvar aortic and pulmonary stenosis, she underwent surgical repair with patch augmentation of the PA and ascending aorta at 4 months old. She has done well post-operatively, continuing on enteral bisphosphonate therapy with no side effects to date. Her identical twin was confirmed to have the same mutation and remains asymptomatic with no calcifications. Aggressive bisphosphonate therapy should be started as soon as possible in patients with infantile arterial calcinosis due to ABCC6 or ENPP1 mutations. Echocardiographic evaluation can be used to monitor disease progression by arterial gradients. Molecular testing is also essential to evaluate for possible co-morbidities in these patients and pregnancy management for the future.